ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company with a current market capitalization of $50.3 million, announced the appointment of Faisal G. Sukhtian as Chairman ...
On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude ...
Clearside Biomedical (CLSD) announced recent and upcoming presentations at ophthalmic medical meetings highlighting Clearside’s suprachoroidal ...
There are lots of interesting companies that make Bedford their home. Here is a quick recap of what’s happening around town ...
Researchers have uncovered vascular “fingerprints” in the eye that are strongly associated with increased risk for stroke.
While there’s some evidence to support these types of treatments, rigorous research studies are still missing. What about its commercial use? This is a rapidly evolving field. Both LED and laser ...
DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...
Teva Pharmaceuticals International GmbH, a subsidiary of Teva, has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, ...
As the company faces criticism for its decision last year to not renew insurance policies for 72,000 property owners in California, State Farm has nixed plans to run a commercial during this year ...
The royalty rights were for 10-years, starting from the date of first commercial sales. Vabysmo was approved in 2022 for wet AMD and diabetic macular edema, and XOMA paid Affitech another $8mn.